Huan Liu

Ms. Huan Liu

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HLHuan Liu
Huan Liu
MCMeilan Chen
Meilan Chen
XLXiaozhe Li
Xiaozhe Li
LKLifen Kuang
Lifen Kuang
JLJingxia Li
Jingxia Li
JLJuan Li
Juan Li
Background/Objectives: The optimal duration of maintaining minimal residual disease (MRD) negative status remains unclear in transplant-eligible newly diagnosed multiple myeloma (TE-NDMM). This single-center retrospective study aimed to explore the minimum duration of sustained MRD negativity with prognostic value. Methods: This research included 223 TE-NDMM patients who achieved at least two consecutive MRD-negative assessments after initial treatment. We analyzed the influence of sustained MRD negativity on survival in different risk stratifications. Results: There was no difference in progression-free survival (PFS) between high-risk (HR) patients with an MRD negativity duration of ≥2 years and patients in the standard-risk (SR) group (70.77 vs. 67.38 months, p = 0.529). In SR patients, PFS showed no significant difference between patients maintaining MRD negativity for 2–3 years and those maintaining MRD negativity for more than 3 years (72.25 months vs. 107.50 months, p = 0.103). In contrast, in the HR group, there was no difference between a duration of 4–5 years and ≥5 years (NR vs. 84.53 months, p = 0.136). A duration over 2 years was associated with superior overall survival (OS) for all patients. Conclusions: Long-term maintenance of MRD-negative status was associated with good prognosis. Sustained MRD negativity for ≥2 years was associated with reducing the adverse influence of high-risk cytogenetics, and a duration over 4 years may be correlated with longer PFS in high-risk multiple myeloma patients in an exploratory analysis based on limited cases.